SAN DIEGO, Sept. 25, 2017 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced
that it will host a key opinion leader (KOL) presentation and
webcast to highlight the current unmet need in post-fracture
therapy and discuss the company's lead program VK5211 for the
treatment of patients following hip fracture surgery. The
event details are as follows:
Date:
|
Monday, October 9,
2017
|
Time:
|
10:00am –
12:00pm
|
Location:
|
Michelangelo
Hotel
|
|
152 W.
51st Street @ 7th Avenue
|
|
Roman Room
|
The event will feature presentations from four speakers, each
with significant experience in the development of novel
musculoskeletal therapeutics or in the treatment of hip and other
fracture patients:
- Keith Marschke, Ph.D., VP,
Biology, Ligand Pharmaceuticals
- Jay Magaziner, Ph.D.,
Epidemiology and Biostatistics Professor and Chair, Department of
Epidemiology and Public Health, University of
Maryland School of Medicine
- Neil Binkley, M.D., Professor,
Department of Medicine - Geriatrics; Co-Director, Osteoporosis
Clinical Center and Research Program, Associate Director, Institute
on Aging, University of Wisconsin School of
Medicine and Public Health
- Jack Guralnik, M.D., Ph.D., MPH,
Professor, Department of Epidemiology and Public Health,
University of Maryland School of
Medicine
A light lunch will be served at conclusion of the event.
Viking recently announced that enrollment has been completed in
the company's ongoing Phase 2 clinical trial of VK5211 in patients
recovering from hip fracture surgery. VK5211, the company's
lead program for muscle and bone disorders, is an orally available,
non-steroidal selective androgen receptor modulator (SARM) designed
to selectively stimulate muscle and bone formation with reduced
activity in peripheral tissues such as skin and prostate. The
company believes these characteristics may provide important
benefits to patients recovering from hip fracture.
The Phase 2 clinical trial is a randomized, double-blind,
placebo-controlled, parallel group study designed to evaluate the
efficacy, safety and tolerability of VK5211 in patients recovering
from hip fracture surgery. A total of 108 patients have been
randomized to receive once-daily VK5211 doses of 0.5 mg, 1.0 mg,
2.0 mg, or placebo for 12 weeks. The study's primary endpoint
will evaluate the effects of VK5211 on lean body mass after 12
weeks of treatment. Secondary and exploratory objectives
include assessments of functional performance, quality-of-life, and
activities of daily living, as well as safety, tolerability and
pharmacokinetics. Viking expects to announce results from
this trial in the fourth quarter.
This event is intended for institutional investors, sell-side
analysts, investment bankers, and business development
professionals only. Space is limited, please RSVP in advance to
attend. To RSVP, please contact Stephanie
Diaz at Vida Strategic Partners
at sdiaz@vidasp.com.
A live and archived webcast of the event will be available on
the Investors section of the company's website
at http://ir.vikingtherapeutics.com/webcasts-and-presentations.
About VK5211
VK5211 is an orally available,
non-steroidal selective androgen receptor modulator (SARM) in Phase
2 development for the treatment of patients recovering from
non-elective hip fracture surgery. VK5211 belongs to a family
of novel orally available, non-steroidal SARM compounds based on
tissue-specific gene expression and other functional, cell-based
technologies. Viking believes that VK5211 has the potential
to produce the therapeutic benefits of testosterone with improved
safety, tolerability and patient acceptance due to a
tissue-selective mechanism of action and an oral route of
administration. In Phase 1 clinical trials, VK5211
demonstrated statistically significant increases in lean body mass
among treated subjects following 21 days of treatment. In a
pre-clinical model of osteoporosis, VK5211 demonstrated
improvements in bone mineral density, bone mineral content, bone
strength, and other measures.
About Viking Therapeutics, Inc.
Viking
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
focused on the development of novel, first-in-class or
best-in-class therapies for metabolic and endocrine
disorders. The company's research and development activities
leverage its expertise in metabolism to develop innovative
therapeutics designed to improve patients' lives. Viking has
exclusive worldwide rights to a portfolio of five therapeutic
programs in clinical trials or preclinical studies, which are based
on small molecules licensed from Ligand Pharmaceuticals
Incorporated. The company's clinical programs include VK5211,
an orally available, non-steroidal selective androgen receptor
modulator, or SARM, in Phase 2 development for the treatment and
prevention of lean body mass loss in patients who have undergone
hip fracture surgery, VK2809, a small molecule thyroid beta agonist
in Phase 2 development for hypercholesterolemia and fatty liver
disease, and VK0612, a first-in-class, orally available drug
candidate in Phase 2 development for type 2 diabetes. Viking
is also developing novel and selective agonists of the thyroid beta
receptor for adrenoleukodystrophy, as well as two earlier-stage
programs targeting metabolic diseases and anemia.
Follow Viking on Twitter @Viking_VKTX.
Forward-Looking Statements
This press release
contains forward-looking statements regarding Viking Therapeutics,
including statements about Viking's expectations regarding its
development activities, timelines and milestones, as well as the
company's goals and plans regarding VK2809 and VK2809's prospects.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially and reported
results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not
limited to: risks associated with the success, cost and timing of
Viking's product candidate development activities and clinical
trials, including those for VK2809; risks that prior clinical and
pre-clinical results may not be replicated; and risks regarding
regulatory requirements, among others. These forward-looking
statements speak only as of the date hereof. Viking disclaims
any obligation to update these forward-looking statements.
View original
content:http://www.prnewswire.com/news-releases/viking-therapeutics-to-host-key-opinion-leader-event-to-discuss-musculoskeletal-therapeutics-in-hip-fracture-and-other-settings-300524813.html
SOURCE Viking Therapeutics, Inc.